Managing chronic renal insufficiency - Intertwined roles of non-nephrologist and nephrologist

Journal of the National Medical Association

Volumn 95, Issue 1, 2003, Pages 43-54

  Ifudu, Onyekachi ^a   Friedman, Eli A ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NONE

Author keywords

Chronic renal insufficiency; Kidney disease; Nephrologist

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA3; TROGLITAZONE;

ACID BASE BALANCE; ANEMIA; ANTIHYPERTENSIVE ACTIVITY; CHRONIC KIDNEY FAILURE; COPING BEHAVIOR; ELECTROLYTE DISTURBANCE; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALNUTRITION; NEPHROLOGY; OUTCOMES RESEARCH; PATIENT EDUCATION; PATIENT REFERRAL; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; REVIEW; UREMIA; VEIN PUNCTURE; COMORBIDITY; GENERAL PRACTITIONER; PHYSICIAN ATTITUDE;

COMORBIDITY; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY FAILURE, CHRONIC; NEPHROLOGY; PHYSICIAN'S ROLE; PHYSICIANS, FAMILY; REFERRAL AND CONSULTATION;

EID: 0037264482     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. United States Renal Data Systems. USRDS. 2000 Annual Data Report. National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases; Bethesda, MD, 2000.
2. th ed. W.B. Saunders Co., Philadelphia, PA. 1991; 919-968.
3. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
4. Carroll HG, Oh MS. Water, Electrolyte and Acid-Base Metabolism. (Eds) J.B. Lippincott Co., Philadelphia, PA. 1989; 117-118.
5. American Diabetes Association. Diabetes Care. 1998;21:1-7.
6. Morbidity and Mortality of Renal Dialysis: An NIH Consensus Conference Statement. Consensus Development Conference Panel. Ann Intern Med. 1994;121:62-70.
7. Bloembergen WE, Young EW, Woods JD, et al. Factors associated with late referral among new dialysis patients in the US [Abstract]. J Am Soc Nephrol. 1997;8:A0870.
8. Arora P, Obrador GT, Ruthazer R, et al. Prevalence, predictors, and consequences of late nephrologic referral at a tertiary care center. J Am Soc Nephrol. 1999;10:1281-6.
9. Obrador GT, Ruthazer R, Arora P, Kausz AT, et al. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol. 1999;10:1791-800.
10. Ifudu O, Dawood M, Homel P, Friedman EA. Excess morbidity in patients starting uremia therapy without prior care by a nephrologist. Am J Kidney Dis. 1996;28:841-845.
11. Ifudu O, Dawood M, Iofel Y, Valcourt JS, Friedman EA. Delayed referral of black, hispanic, and older patients with chronic renal failure. Am J Kidney Dis. 1999;33:728-733.
12. Eadington DW. Delayed referral for dialysis: higher morbidity and higher costs. Seminars in Dialysis. 1995;8:258-260.
13. Bonomini V, Feletti C, Scolari MP, Stefoni S. Benefits of early initiation of dialysis. Kidney Inter. 1985;28:S57-S59.
14. Walker PD, Barri Y, Shah SV. Oxidant mechanisms in gentamicin nephrotoxicity. Ren Fail. 1999;21:433-42.
15. Nortier JL, Martinez MC, Schmeiser HH. Urothelial carcinoma associated with the use of a chinese herb. N Engl J Med. 2000;342:1686-92.
16. Rao TKS, Friedman EA, Nicastri AD. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med. 1987;316:1062-8.
17. Mann SJ, Pickering TG. Detection of renovascular hypertension. State of the art. Ann Intern Med. 1992;117:845-53.
18. McCormack JP, Cooper J, Carleton B. Simple approach to dosage adjustment in patients with renal impairment. Syst Pharm. 1997;54:2505-2509.
19. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-20.
20. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180-4.
21. Rosansky SJ, Hoover DR, King L, et al. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med. 1990;150:2073-2076.
22. Moore MA, Epstein M, Agodoa L, et al. Current strategies for management of hypertensive renal disease. Arch Intern Med. 1999;159:23-28.
23. Maiorca R, Scolari F, Cancarini G, et al. Management of hypertension in chronic renal failure. Contrib Nephrol. 1987;54:190-201.
24. Giatras I, Lau J, Levey AS. Effect of angiotensin converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med. 1997;127:337-345.
25. Zucchelli P, Zuccala A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int. 1992;42:452-458.
26. Maschio G, Albert D, Janin G, et al. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939-945.
27. Sharma K, Eltayeb BO, McGowan TA, et al. Captopril-induced reduction of serum levels of transforming growth factor-beta correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis. 1999;34:818-23.
28. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med. 1993;153:973-80.
29. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998;339:1448-56.
30. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotecive effect of ACE-inhibition in nondiabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359-64.
31. Nyberg G, Bhlomé G, NordJn G. Input of metabolic control on progression of clinical diabetic nephropathy. Diabetologia. 1987;30:82-86.
32. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995;47:1703-1720.
33. Delahanty LM. Implications of the diabetes control and complications trial for renal outcomes and medical nutrition therapy. J Ren Nutr. 1998;8:59-63.
34. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Copley-Merriman C, Maier W, Dong F, Manninen D, Zbrozek AS, Kotsanos J, Garfield SA, Harris M. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating Type 2 diabetes with the goal of normoglycemia. Diabetes Care. 1997;20:735-744.
35. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837-853.
36. Sambol NC, Chiang J, Lin ET, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35:1094-102.
37. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158:998-1004.
38. Cappelli P, Di Liberato L, Albertazzi A. Role of dyslipidemia in the progression of chronic renal disease. Ren Fail. 1998;20:391-397.
39. Rosman JB, Ter Wee PM, Piers-Becht TPM et al. Prospective randomized trial of early dietary protein restriction in chronic renal failure. Lancet. 1984;II:1291-1296.
40. Locatelli F, Alberti D, Graziani G, Guccianti G, Redaelli B, Giangrande A. Prospective randomized multicenter trial of effect of protein restriction on progress of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet. 1991;337:1299-1304.
41. Williams PS, Stevens ME, Fass G, Irons L, Bone JM. Failure of dietary protein restriction and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial. Am J Med. 1991;294:837-855.
42. Klahr S, Levey AS, Beck GJ et al. and the Modification of Diet in Renal Disease Study Group. the effects of dietary protein restriction and blood pressure control on the progression of renal disease. N Engl J Med. 1994;330:877-884.
43. Zeller K, Whittaker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1991;324:78-84.
44. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal disease: a meta-analysis. Ann Intern Med. 1996;124:627-632.
45. Pijls LTJ, de Vried H, Donker AJM, van Eijk JTM. The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transplant. 1999;14:1445-1453.
46. Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, Klahr S. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol. 1999;11:2426-39.
47. Silverberg D, Blum M, Peer G, et al. Anemia during the predialysis period: a key to cardiac damage in renal failure. Nephron. 1998;80:1-5.
48. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27:347-54.
49. Drueke TB, Eckardt KU, Frei U, et al. Does early anemia correction prevent complications of chronic renal failure? Clin Nephrol. 1999;51:1-11.
50. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy fro predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548-54.
51. Qiao Q, Keinanen-Kiukaanniemi S, Laara E. The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol. 1997;50:153-8
52. Friedman EA, Brown CD, Berman DH. Erythropoietin in diabetic macular edema and renal insufficiency. Am J Kidney Disease. 1995;1:202-208.
53. Krmar RT, Gretz N, Klare B, et al. Renal function in predialysis children with chronic renal failure treated with erythropoietin. Ped Nephrol. 1997;11:69-73.
54. Kuriyama S, Tomonari H, Yoshida H, et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176-85.
55. Ifudu O, Cohen LS, Mayers JD, et al. Residual renal function modulates response to recombinant erythropoietin in patients with progressive chronic renal failure. J Am Soc Nephrol. 1999;10:76A.
56. Macdougall IC. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant. 1999;14:1836-41.
57. Delmez JA, Slatopolsky E. Recent advances in the pathogenesis and therapy of uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1991;72:735-739.
58. Alpern RJ, Sakhaee K. Clinical spectrum of chronic metabolic acidosis: homeostatic mechanisms produce significant morbidity. Am J Kidney Dis. 1997;29:291-302.
59. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 1996;335:1897-905.
60. Hou S. Pregnancy in women with chronic renal disease. N Engl J Med. 1985;312:836-9.
61. Winston JA, Burns GC, Klotman PE. Treatment of HIV-associated nephropathy. Semin Nephrol. 2000;20:293-8.
62. Ifudu O, Mayers JD, Matthew JJ, et al. Uremia therapy in patients with end-stage renal disease and human immunodeficiency virus infection: has the outcome changed in the 1990s. Am J Kidney Dis. 1997;29:549-52.
63. Barth RH. Long survival of chronically dialyzed patients with human immunodeficiency virus disease. J Am Soc Nephrol. 1996;7:A0954
64. Kimmel PL, Mishkin GJ, Umana WO. Captoril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis. 1996;28:202-8.
65. Ifudu O, Rao TKS, Tan CC, Fleischman H, Chirgwin K, Friedman EA. Zidovudine is beneficial in human immunodeficiency virus-associated nephropathy. Am J Nephrol. 1995;15:217-221.
66. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med. 1983;308:8-12.
67. NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis. 1997;30:S150-91.
68. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996;7:523-35.
69. Ifudu O. Timing of initiation of uremia therapy: where is the science? Int J Artif Org. 1997;20:601-602.
70. Scribner B. A critical comment. Nephron. 1976;16:100-102.
71. Berlyne GM, Giovannetti S. When would entry into a regular hemodialysis occur? Nephron. 1976;16:81-82.
72. Maher JF. When should maintenance dialysis be initiated? Nephron. 1976;16:83-88.